These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32843034)

  • 1. Radiation oncologists' attitudes and beliefs about intensity-modulated radiation therapy and stereotactic body radiation therapy for prostate cancer.
    Jacobs BL; Hamm M; de Abril Cameron F; Luiggi-Hernandez JG; Heron DE; Kahn JM; Barnato AE
    BMC Health Serv Res; 2020 Aug; 20(1):796. PubMed ID: 32843034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
    Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD
    J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
    Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Schroeck FR; Bekelman JE; Kahn JM; Nelson JB; Barnato AE
    Cancer; 2017 Aug; 123(15):2945-2954. PubMed ID: 28301689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Stereotactic body radiation therapy versus conventional intensity-modulated radiation therapy for the treatment of prostate cancer].
    Gao QN
    Zhonghua Nan Ke Xue; 2019 May; 25(5):424-429. PubMed ID: 32216228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
    Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
    Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
    Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
    Dee EC; Muralidhar V; King MT; Martin NE; D'Amico AV; Mouw KW; Orio PF; Nguyen PL; Leeman JE
    Radiother Oncol; 2021 Aug; 161():241-250. PubMed ID: 34171451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiation therapy for prostate cancer-a review.
    Haque W; Butler EB; Teh BS
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
    Yu JB; Cramer LD; Herrin J; Soulos PR; Potosky AL; Gross CP
    J Clin Oncol; 2014 Apr; 32(12):1195-201. PubMed ID: 24616315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
    Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
    Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
    Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
    Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
    Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
    Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer.
    Hodges JC; Lotan Y; Boike TP; Benton R; Barrier A; Timmerman RD
    Am J Manag Care; 2012 May; 18(5):e186-93. PubMed ID: 22694113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral Determinants of Canadian Radiation Oncologists' Use of Single Fraction Palliative Radiation Therapy for Uncomplicated Bone Metastases.
    Squires JE; Asad S; Varin MD; Dorrance K; Chow E; Fairchild A; Wong R; Graham ID; Grimshaw JM; Dennis K
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):374-386. PubMed ID: 32966890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Influence of Health Insurance Policy on Radiation Oncology Physician SBRT/SABR Use Practices: A North American Survey.
    Guo J; Kim H; Kalchman I; Dan TD; Zhan T; Werner-Wasik M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):524-529. PubMed ID: 29280445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National variation in the delivery of radiation oncology procedures in the non-facility-based setting.
    Valle LF; Chu FI; Kundu P; Yoon SM; Gilchrist T; Steinberg ML; Raldow AC
    Cancer Med; 2021 Jul; 10(14):4734-4742. PubMed ID: 34076341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
    Evans JR; Zhao S; Daignault S; Sanda MG; Michalski J; Sandler HM; Kuban DA; Ciezki J; Kaplan ID; Zietman AL; Hembroff L; Feng FY; Suy S; Skolarus TA; McLaughlin PW; Wei JT; Dunn RL; Finkelstein SE; Mantz CA; Collins SP; Hamstra DA;
    Radiother Oncol; 2015 Aug; 116(2):179-84. PubMed ID: 26276528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
    Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: Quality Assurance of a Randomized Phase 2 Trial.
    Jaccard M; Zilli T; Dubouloz A; Escude L; Jorcano S; Linthout N; Bral S; Verbakel W; Bruynzeel A; Björkqvist M; Minn H; Tsvang L; Symon Z; Lencart J; Oliveira A; Ozen Z; Abacioglu U; Pérez-Moreno JM; Rubio C; Rouzaud M; Miralbell R
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1047-1054. PubMed ID: 32535161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.